Wijnand Helfrich
Overview
Explore the profile of Wijnand Helfrich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
1368
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Volaric J, van der Heide N, Mutter N, Samplonius D, Helfrich W, Maglia G, et al.
ACS Chem Biol
. 2024 Feb;
19(2):451-461.
PMID: 38318850
Enabling control over the bioactivity of proteins with light, along with the principles of photopharmacology, has the potential to generate safe and targeted medical treatments. Installing light sensitivity in a...
2.
Ploeg E, Samplonius D, Xiong X, Ke X, Hendriks M, Britsch I, et al.
J Immunother Cancer
. 2023 Sep;
11(9).
PMID: 37734877
Background: CD73 is an ecto-enzyme that is involved in the conversion of pro-inflammatory extracellular ATP (eATP) excreted by cancer cells under stress to anti-inflammatory adenosine (ADO). A broad variety of...
3.
Britsch I, van Wijngaarden A, Helfrich W
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568582
Infection with cytomegalovirus (CMV) is highly prevalent in the general population and largely controlled by CD8 T cells. Intriguingly, anti-CMV T cells accumulate over time to extraordinarily high numbers, are...
4.
Ploeg E, Britsch I, van Wijngaarden A, Ke X, Hendriks M, Samplonius D, et al.
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509310
PD-1/PD-L1-inhibiting antibodies have shown disappointing efficacy in patients with refractory ovarian cancer (OC). Apparently, OC cells exploit nonoverlapping immunosuppressive mechanisms to evade the immune system. In this respect, the CD73-adenosine...
5.
Britsch I, van Wijngaarden A, Ke X, Hendriks M, Samplonius D, Ploeg E, et al.
Oncoimmunology
. 2023 May;
12(1):2207868.
PMID: 37180637
Typically, anticancer CD8 T cells occur at low frequencies and become increasingly impaired in the tumor micro environment. In contrast, antiviral CD8 T cells display a much higher polyclonality, frequency,...
6.
van der Zant F, Kooijman B, Hentzen J, Helfrich W, Ploeg E, van Ginkel R, et al.
BJS Open
. 2022 Oct;
6(5).
PMID: 36218348
Background: The aim of this study was to evaluate the impact of all minor and major complications on treatment-related healthcare costs in patients who undergo cytoreductive surgery (CRS) with hyperthermic...
7.
Xiong X, Ke X, Wang L, Lin Y, Wang S, Yao Z, et al.
J Extracell Vesicles
. 2022 Aug;
11(8):e12243.
PMID: 35927827
Cancer vaccines critically rely on the availability of targetable immunogenic cancer-specific neoepitopes. However, mutation-based immunogenic neoantigens are rare or even non-existent in subgroups of cancer types. To address this issue,...
8.
Helbert H, Ploeg E, Samplonius D, Blok S, Antunes I, Bohmer V, et al.
EJNMMI Radiopharm Chem
. 2022 Mar;
7(1):3.
PMID: 35239034
Background: Pretargeted immuno-PET tumor imaging has emerged as a valuable diagnostic strategy that combines the high specificity of antibody-antigen interaction with the high signal and image resolution offered by short-lived...
9.
Hendriks M, Britsch I, Ke X, van Wijngarden A, Samplonius D, Ploeg E, et al.
Oncoimmunology
. 2021 Dec;
10(1):2005344.
PMID: 34858730
Cancer cells exploit CD47 overexpression to inhibit phagocytic elimination and neoantigen processing via the myeloid CD47-SIRPα axis and thereby indirectly evade adaptive T cell immunity. Here, we report on a...
10.
Ploeg E, Ke X, Britsch I, Hendriks M, van der Zant F, Kruijff S, et al.
Cancer Lett
. 2021 Aug;
521:109-118.
PMID: 34464670
Tumor-derived extracellular vesicles (EVs) carry potent immunosuppressive factors that affect the antitumor activities of immune cells. A significant part of the immunoinhibitory activity of EVs is attributable to CD73, a...